Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis

Journal of the American Academy of Dermatology
Amy S PallerRichard G Langley

Abstract

There are no systemic therapies approved in the United States to treat pediatric psoriasis. We sought to evaluate long-term safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis. This 5-year, open-label extension study enrolled patients aged 4 to 17 years who had participated in a 48-week parent study. End points included occurrence of adverse events (AEs) and serious AEs including infections, and rates of 75% and 90% improvement in Psoriasis Area and Severity Index score and clear/almost clear on static physician global assessment. Of 182 patients enrolled, 181 received etanercept and 69 completed 264 weeks. Through week 264, 161 (89.0%) patients reported an AE, most commonly upper respiratory tract infection (37.6%), nasopharyngitis (26.0%), and headache (21.5%). Seven patients reported 8 serious AEs; only 1 (cellulitis) was considered treatment-related. No cases of opportunistic infections or malignancy were reported. Rates of 75% improvement in Psoriasis Area and Severity Index score (∼ 60%-70%) and 90% improvement in Psoriasis Area and Severity Index score (∼ 30%-40%) and static physician global assessment status clear/almost clear (∼ 40%-50%) were maintained through week 26...Continue Reading

References

Jan 1, 1974·Dermatologica·E M Farber, M L Nall
Jul 8, 2000·Pediatric Dermatology·S P Raychaudhuri, J Gross
May 30, 2006·Arthritis and Rheumatism·Daniel J LovellUNKNOWN Pediatric Rheumatology Collaborative Study Group
Jan 18, 2008·The New England Journal of Medicine·Amy S PallerUNKNOWN Etanercept Pediatric Psoriasis Study Group
Apr 29, 2008·Arthritis and Rheumatism·Daniel J LovellUNKNOWN Pediatric Rheumatology Collaborative Study Group
Jun 13, 2009·The British Journal of Dermatology·D BoccardiM Ferraroni
Aug 29, 2009·Arthritis and Rheumatism·E H GianniniUNKNOWN Pediatric Rheumatology Collaborative Study Group
Nov 20, 2009·The British Journal of Dermatology·M AugustinI Schäfer
Dec 8, 2009·Journal of the American Academy of Dermatology·Megha M TollefsonHilal Maradit Kremers
Jul 8, 2010·Journal of the American Academy of Dermatology·Amy S PallerGreg Kricorian
Sep 21, 2010·Journal of the American Academy of Dermatology·Kim A PappJerry Syrotuik
Nov 17, 2010·Pediatric Dermatology·Ayhan BilgicEmine Zinnur Kılıç
Apr 29, 2011·The Journal of Pediatrics·Corinna KoebnickJashin J Wu
Sep 21, 2011·Archives of Dermatology·Sinae A VogelKelly M Cordoro
Nov 8, 2011·JAMA : the Journal of the American Medical Association·Marieke H OttenLisette W A van Suijlekom-Smit
Dec 2, 2011·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Zbigniew ZuberEwa Tuszkiewicz-Misztal
Apr 15, 2014·Adolescent Health, Medicine and Therapeutics·Robin K Dore
Oct 28, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·M J van GeelM M B Seyger

❮ Previous
Next ❯

Citations

Apr 18, 2016·Dermatology and Therapy·Maddalena NapolitanoNicola Balato
Jun 6, 2017·Current Opinion in Pediatrics·Jennifer Aileen Ang Tangtatco, Irene Lara-Corrales
Jun 19, 2017·Journal of the American Academy of Dermatology·Kelly M CordoroMichael D Rosenblum
Jul 25, 2017·International Journal of Dermatology·Martin Havmose, Simon Francis Thomsen
Dec 23, 2017·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Fang XieYong Zhou
Aug 23, 2017·Expert Opinion on Biological Therapy·Vito Di Lernia
Sep 30, 2017·International Journal of Dermatology·Rita Ramos PinheiroMaria J P Lopes
Mar 19, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·C PhanUNKNOWN Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie
Jul 5, 2019·Expert Opinion on Pharmacotherapy·S D'AdamioM Galluzzo
Feb 6, 2020·JAMA Dermatology·Inge M G J BronckersUNKNOWN Psoriasis Investigator Group, the Pediatric Dermatology Research Alliance, and the European Working Group on Pediatric Psori
Mar 18, 2020·Expert Opinion on Drug Safety·Anna CampanatiAnnamaria Offidani
Aug 9, 2017·The Journal of Dermatological Treatment·Vito Di LerniaSerafinella P Cannavò
May 1, 2020·Paediatric Drugs·Quoc-Bao D NguyenAdelaide A Hebert
Jun 12, 2020·Clinical Microbiology Reviews·Joshua S DavisMichael Boyle
Jul 14, 2017·Therapeutic Drug Monitoring·Sara MuriasDenis Mulleman
Aug 25, 2017·European Journal of Pediatrics·Anna Belloni FortinaAlberto Villani
Sep 14, 2019·Children·Abigail ClineSteven R Feldman
Apr 1, 2021·Expert Review of Clinical Pharmacology·Emmanuel MahéCéline Phan
Apr 17, 2021·American Journal of Clinical Dermatology·Akshitha ThatiparthiJashin J Wu
Jun 10, 2021·Expert Opinion on Biological Therapy·Jennifer Clay CatherJ Christian Cather
Oct 29, 2021·Experimental and Therapeutic Medicine·Daciana Elena BranisteanuDaniel Constantin Branisteanu
May 3, 2019·Pediatrics·Michael A PortmanUNKNOWN EATAK Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

Related Papers

Journal of the American Academy of Dermatology
Amy S PallerGreg Kricorian
Clinics in Dermatology
Hideaki SugiyamaNeil J Korman
Journal of the European Academy of Dermatology and Venereology : JEADV
R Jiménez-PuyaJ C Moreno-Giménez
© 2022 Meta ULC. All rights reserved